ABBV-321 in Advanced Solid Tumors with Overexpression of EGFR

What is the Purpose of this Study?

We are doing this study to learn if the new drug, ABBV-321 is safe when given to patients with colorectal cancer or glioblastoma.

We start with a Dose Escalation phase is to find the highest dose that can be safely tolerated by patients, which is called the Maximum Tolerated Dose (MTD).

We then do an Expanded Safety phase to get a better understanding of the safety of the drug at the MTD in a larger number of people.
What is the Condition Being Studied?
Colorectal cancer or Glioblastoma (brain tumor)

Who Can Participate in this Study?

Adults who are diagnosed with colorectal cancer or glioblastoma.

Age Group
Adults
Participating Institutions

What is Involved?

There are two phases to this study:

Phase 1 is where the study drug ABBV-321 will be given through a vein once every 28 days and will be given in higher doses until we can get the highest and safest dose.

Phase 2 is where patients will be watched for side effects (good or bad) of the study drug ABBV-321 (given through a vein) at the dose found in Phase 1.

Study Details

Full Title
Phase 1 Study Evaluating the Safety, Pharmacokinetics, and Anti-Tumor Activity of ABBV-321 in Subjects with Advanced Solid Tumors Associated with Overexpression of the Epidermal Growth Factor Receptor (EGFR)
Principal Investigator

Contacts
Gastrointestinal Oncology DCI Clinical Research Team
Protocol Number
IRB:
PRO00086471

NCT:
NCT03234712
ClinicalTrials.gov
View on ClinicalTrials.gov